|
|
|
For other announcements of interest to the medical community, choose a subcategory from the menu on the left.
|
|
|
|
|
Webcasts from the 43rd Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois. |
|
|
|
|
|
Data Presented at the ASCO Cancer Conference |
|
|
|
|
|
In an article entitled "The Legacy of the World Trade Center Dust," physicians say more than 5 years after the World Trade Center disaster, "uncertainty and controversy remain about the health risks posed by inhaling dust, the subsequent fires and the cleanup effort." |
|
|
|
|
|
The IMWG, which is comprised of 85 investigators specializing in the area of multiple myeloma, has reviewed and considered the recent Mayo Clinic consensus statement for the use of bisphosphonates (BPs) in multiple myeloma. Although the IMWG is in general agreement with the Mayo consensus statement, several important issues have been raised. |
|
|
|
|
|
Several recent public health advisories and safety messages have raised cautions about the use of Darbopoetin alfa (Aranesp®) and Epoetin alfa (Procrit® and Epogen®). These drugs are used to stimulate red blood cell production to reverse anemia. |
|
|
|
|
mSmart (Mayo Stratification of Myeloma and Risk-Adapted Therapy).
This consensus statement from the Mayo Clinic is excellent overview of the issues and a good basis for discussion as the scientific and clinical communities work to advance the standard of care. |
|
|
|
|
This article is the result of the efforts of the International Myeloma Working Group. |
|
|
|
|
A multidisciplinary panel consisting of hematologists, dental specialists, and nurses specializing in the treatment of myeloma reviewed available data concerning the use of bisphosphonates. Guidelines for the use of bisphosphonates in MM were developed. This link is to the full article. |
|
|
|
|
|
These guidelines encompass both the published literature and expert opinions. Recommendations based upon expert opinions are identified as such. The intent is for the guidelines to be international in scope, plus provide recommendations for both clinical practice and research approaches. This article appeared in The Hematology Journal (2003) 4, 379-398. |
|
|
print
back to top